Newron completes screening for ENIGMA-TRS 1 Phase 3 enrollment
Newron Pharmaceuticals said it has completed screening for enrollment in its pivotal Phase 3 ENIGMA-TRS 1 study. Evenamide will be used as add-on therapy in patients with treatment-resistant schizophrenia.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.